中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
7期
673-676
,共4页
阿托伐他汀%慢性肺源性心脏病%肺动脉高压%超敏C反应蛋白%白细胞介素8
阿託伐他汀%慢性肺源性心髒病%肺動脈高壓%超敏C反應蛋白%白細胞介素8
아탁벌타정%만성폐원성심장병%폐동맥고압%초민C반응단백%백세포개소8
Atorvastatin%Chronic pulmonary heart disease%Pulmonary hypertension%High sensitive C-reaction protein%Interleukin-8
目的 探讨阿托伐他汀对慢性肺源性心脏病(肺心病)患者肺动脉高压的影响及其机制.方法 将68例肺心病慢性缓解期患者随机分为治疗组(35例)和观察组(33例),选取同期进行体检的健康人30名作为正常组.两组患者均接受常规治疗,观察组在常规治疗的基础上加用阿托伐他汀(20mg/d),观察两组治疗前、治疗后6个月肺功能、超声心动图、血浆中超敏C反应蛋白(hs-CRP)、白细胞介素8(IL-8)水平的变化.结果 治疗组、观察组血浆中hs-CRP,IL-8浓度及肺动脉压(PAP)治疗前明显高于正常组(t值分别为2.87,2.79,3.01,3.28,3.31,3.15；P值分别为0.005,0.007,0.004,0.001,0.001,0.002).观察组治疗6个月后PAP、hs-CRP、IL-8较治疗前和治疗组治疗6个月后明显下降(t值分别为2.17,2.59,2.63,1.91,1.86,1.74；P值分别为0.039,0.008,0.007,0.031,0.037,0.042),第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)指标比治疗组治疗6个月后有明显改善(t值分别为1.84,2.13;P值分别为0.037,0.024)；治疗组治疗前与治疗后6个月上述指标比较差异均无统计学意义(P均＞0.05).结论 阿托伐他汀可以改善慢性肺心病患者生活质量及肺功能、降低PAP,这些作用可能与阿托伐他汀抑制肺血管炎性反应有关.
目的 探討阿託伐他汀對慢性肺源性心髒病(肺心病)患者肺動脈高壓的影響及其機製.方法 將68例肺心病慢性緩解期患者隨機分為治療組(35例)和觀察組(33例),選取同期進行體檢的健康人30名作為正常組.兩組患者均接受常規治療,觀察組在常規治療的基礎上加用阿託伐他汀(20mg/d),觀察兩組治療前、治療後6箇月肺功能、超聲心動圖、血漿中超敏C反應蛋白(hs-CRP)、白細胞介素8(IL-8)水平的變化.結果 治療組、觀察組血漿中hs-CRP,IL-8濃度及肺動脈壓(PAP)治療前明顯高于正常組(t值分彆為2.87,2.79,3.01,3.28,3.31,3.15；P值分彆為0.005,0.007,0.004,0.001,0.001,0.002).觀察組治療6箇月後PAP、hs-CRP、IL-8較治療前和治療組治療6箇月後明顯下降(t值分彆為2.17,2.59,2.63,1.91,1.86,1.74；P值分彆為0.039,0.008,0.007,0.031,0.037,0.042),第1秒用力呼氣容積(FEV1)、FEV1/用力肺活量(FVC)指標比治療組治療6箇月後有明顯改善(t值分彆為1.84,2.13;P值分彆為0.037,0.024)；治療組治療前與治療後6箇月上述指標比較差異均無統計學意義(P均＞0.05).結論 阿託伐他汀可以改善慢性肺心病患者生活質量及肺功能、降低PAP,這些作用可能與阿託伐他汀抑製肺血管炎性反應有關.
목적 탐토아탁벌타정대만성폐원성심장병(폐심병)환자폐동맥고압적영향급기궤제.방법 장68례폐심병만성완해기환자수궤분위치료조(35례)화관찰조(33례),선취동기진행체검적건강인30명작위정상조.량조환자균접수상규치료,관찰조재상규치료적기출상가용아탁벌타정(20mg/d),관찰량조치료전、치료후6개월폐공능、초성심동도、혈장중초민C반응단백(hs-CRP)、백세포개소8(IL-8)수평적변화.결과 치료조、관찰조혈장중hs-CRP,IL-8농도급폐동맥압(PAP)치료전명현고우정상조(t치분별위2.87,2.79,3.01,3.28,3.31,3.15；P치분별위0.005,0.007,0.004,0.001,0.001,0.002).관찰조치료6개월후PAP、hs-CRP、IL-8교치료전화치료조치료6개월후명현하강(t치분별위2.17,2.59,2.63,1.91,1.86,1.74；P치분별위0.039,0.008,0.007,0.031,0.037,0.042),제1초용력호기용적(FEV1)、FEV1/용력폐활량(FVC)지표비치료조치료6개월후유명현개선(t치분별위1.84,2.13;P치분별위0.037,0.024)；치료조치료전여치료후6개월상술지표비교차이균무통계학의의(P균＞0.05).결론 아탁벌타정가이개선만성폐심병환자생활질량급폐공능、강저PAP,저사작용가능여아탁벌타정억제폐혈관염성반응유관.
Objective To explore the effect and mechanism of atorvastatin on pulmonary hyper-tension in chronic pulmonary heart disease.Methods Sixty eight patients with chronic pulmonary heart disease were randomly divided into treatment group (n=35) and observation group ( n=33 ).Thirty healthy people were picked up from people taking physical examination at the same stage as control group.Patients in both treatment and observation groups were given routine treatment and the observation group were given atorvastatin (20 mg/d) supplement.Changes in pulmonary function,ultrasound cardiogram,plasma high-sensitive C-reactive protein (hs-CRP) and interleukin (IL-8) were observed before and after 6 months of treatment.Results The levels of hs-CRP,IL-8 and pulmonary arterial pressure in treatment and observation groups are higher than that in normal group before treatment (t=2.87,2.79,3.01,3.28,3.31,3.15,respectively,and P =0.005,0.007,0.004,0.001,0.001,0.002,respectively).The pulmonary arterial pressure,hs-CRP,IL-8 in observation group after treated for 6 months were significantly lower than those before treatment and in treatment group (t=2.17,2.59,2.63,1.91,1.86,1.74,respectively,and P =0.039,0.008,0.007,0.031,0.037,0.042,respectively).The pulmonary function indexes including FEV1 and FEV1/FVC in observation group were much better than those in treatment group after 6 months treatment (t=1.84,2.13,respectively,and =0.037,0.024,respectively).There were no significant differences on these indicators in treatment group after 6 months treatment when compared with before treatment ( P ＞ 0.05 ).Conclusion Atorvastatin can effectively improve the life quality and pulmonary function,decrease pulmonary arterial pressure of patients with chronic pulmonary heart disease.These effects may be related to the inhibition of inflammation in pulmonary vessels.
